...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates—Toronto Sunnybrook Regional Cancer Centre experience
【24h】

Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates—Toronto Sunnybrook Regional Cancer Centre experience

机译：姑息放疗在双膦酸盐治疗的乳腺癌骨转移患者中的应用-多伦多森尼布鲁克地区癌症中心的经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The use of both bisphosphonates and palliative radiotherapy for the prevention and treatment of skeletal complications in women with bone metastases from breast cancer is well established. We undertook an evaluation of palliative radiotherapy utilization rates in breast cancer patients who received bisphosphonates for the treatment of bone metastases in a major Canadian cancer center. Methods: Charts and electronic files of breast cancer patients with bone metastases who had received either clodronate or pamidronate at any time between January 2000 and December 2001 at our center were retrospectively reviewed. The utilization rates of palliative radiotherapy in these patients were examined.Results: The percentage of patients receiving bisphosphonates for the treatment of bone metastases who also received palliative radiotherapy to bone remained relatively constant over our study period in the range of 70%. In patients commenced on bisphosphonates before 1998, 42.9% received palliative radiotherapy as initial therapy for bone metastases, whereas in 2001 only 27.8% of patients received palliative radiotherapy before commencing bisphosphonate therapy. There has been a marked improvement in the time between the diagnosis of bone metastases and the commencement of bisphosphonates from a median of 446 days before 1998 to 21 days in 2001. At the same time, there was also an improvement in time between diagnosis of bone metastases and initiation of palliative radiotherapy from a median of 265 days before 1998 to 49 days in 2001. Conclusion: Use of bisphosphonates has not reduced the utilization rates of palliative radiotherapy in breast cancer patients with bone metastases. There is a trend of initiating bisphosphonates before delivery of palliative radiotherapy. The latter was also delivered earlier in the course of bone metastases.
机译：背景：使用双膦酸盐和姑息放疗来预防和治疗患有乳腺癌骨转移的女性的骨骼并发症已广为接受。我们对加拿大主要癌症中心接受双膦酸盐治疗骨转移的乳腺癌患者的姑息放疗利用率进行了评估。方法：回顾性分析2000年1月至2001年12月期间在我中心接受氯膦酸盐或帕米膦酸盐治疗的乳腺癌骨转移患者的图表和电子文件。结果：在我们的研究期间，接受双膦酸盐治疗骨转移的患者中也接受姑息放疗的患者所占的百分比相对稳定，保持在70％的范围内。在1998年之前开始使用双膦酸盐治疗的患者中，有42.9％接受姑息放疗作为骨转移的初始疗法，而在2001年，只有27.8％的患者在开始双膦酸盐治疗之前接受了姑息放疗。从1998年之前的446天到2001年的21天的中位时间，从诊断骨转移到开始双膦酸盐治疗的时间已得到显着改善。同时，也缩短了诊断骨的时间转移和姑息放疗的开始时间从1998年之前的265天到2001年的49天。结论：使用双膦酸盐并没有降低乳腺癌骨转移患者的姑息放疗利用率。在进行姑息性放疗之前，有一种开始使用双膦酸盐的趋势。后者也是在骨转移过程中较早交付的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号